GSK (GSK) announced that the National Medical Products Administration, NMPA, of China has accepted for review a new drug application, NDA, for Blenrep in combination with bortezomib plus dexamethasone as a treatment for relapsed or refractory multiple myeloma. Earlier this year, the NMPA granted priority review for this application as well as Breakthrough Therapy Designation for the BVd combination, which is intended to expedite development of investigational drugs with potential for substantial improvement over available therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces U.S. FDA accepted its submission for use of Nucala in COPD
- GSK, Zhifei revise, extend strategic vaccine collaboration in China
- GSK price target lowered to 1,600 GBp from 1,820 GBp at Berenberg
- GSK announces EC approved single-vial presentation of Menveo
- GSK announces FDA accepeted for review a BLA for Blenrep